Open AccessComparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes
Author(s) -
Stefanie Schreiber,
Susan Landau,
Allison Fero,
Frank Schreiber,
William J. Jagust
Publication year - 2015
Publication title -
jama neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.298
H-Index - 231
eISSN - 2168-6157
pISSN - 2168-6149
DOI - 10.1001/jamaneurol.2015.1633
Subject(s) - positron emission tomography , neuroimaging , context (archaeology) , psychology , medicine , nuclear medicine , magnetic resonance imaging , biomarker , radiology , psychiatry , paleontology , biology , biochemistry , chemistry
The applicability of β-amyloid peptide (Aβ) positron emission tomography (PET) as a biomarker in clinical settings to aid in selection of individuals at preclinical and prodromal Alzheimer disease (AD) will depend on the practicality of PET image analysis. In this context, visual-based Aβ PET assessment seems to be the most feasible approach.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom